Lymphopenia News and Research

RSS
Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Receptos begins RPC1063 Phase 1 clinical study in patients with multiple sclerosis

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Results of custirsen Phase 2 trial for advanced prostate cancer published in Journal of Clinical Oncology

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

New data on Cladribine Tablets presented at AAN annual meeting

New data on Cladribine Tablets presented at AAN annual meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis